1y return+110.5%S&P 500 +20.9%
3y return+108.6%S&P 500 +68.5%
These returns are for its stock picks as disclosed on Form 13F: last quarter's holdings, valued at this quarter's prices. They miss trades within each quarter, short positions, options, bonds, cash and fees, so they aren't the returns its clients got.
$100 invested in its stock picks
Since December 31, 2021: $198 against $157 in the S&P 500.2
Paradigm Biocapital Advisors LPS&P 500 (SPY)
Top holdings
At the end of June 30, 2026. Change is in shares since the quarter before.2
| Stock | Value | Share of portfolio | Change |
|---|---|---|---|
| RVMDRevolution Medicines Inc | $1.2B | 22.3% | −4.4% |
| Nuvalent IncCUSIP 670703107 | $731.7M | 13.7% | +11.3% |
| EWTXEdgewise Therapeutics Inc | $415.1M | 7.8% | +38.7% |
| GMABGenmab A/s | $360.8M | 6.8% | +64.8% |
| SYRESpyre Therapeutics Inc | $341.0M | 6.4% | +96.2% |
| Apogee Therapeutics IncCUSIP 03770N101 | $209.2M | 3.9% | +16.9% |
| ORKAOruka Therapeutics Inc | $204.1M | 3.8% | −7.6% |
| TNGXTango Therapeutics Inc | $198.7M | 3.7% | +58.6% |
| BLTEBelite Bio Inc | $189.8M | 3.6% | +10.6% |
| ERASErasca Inc | $175.0M | 3.3% | −8.1% |
| TARSTarsus Pharmaceuticals Inc | $174.7M | 3.3% | +8.3% |
| ALNYAlnylam Pharmaceuticals Inc | $144.5M | 2.7% | New |
| INSMInsmed Inc | $141.4M | 2.6% | +5.7% |
| MBXMbx Biosciences Inc | $138.4M | 2.6% | New |
| PCVXVaxcyte Inc | $123.7M | 2.3% | −55.6% |
| VRDNViridian Therapeutics Inc | $123.5M | 2.3% | +113.5% |
| OLMAOlema Pharmaceuticals Inc | $108.5M | 2.0% | +8.1% |
| JBIOJade Biosciences Inc | $63.5M | 1.2% | New |
| TYRATyra Biosciences Inc | $58.4M | 1.1% | −11.0% |
| ASMBAssembly Biosciences Inc | $42.7M | 0.8% | +133.6% |
| EYPTEyepoint Inc | $41.3M | 0.8% | −8.0% |
| ACHVAchieve Life Science Inc | $32.3M | 0.6% | New |
| VORVor Biopharma Inc | $32.2M | 0.6% | |
| MPLTMaplight Therapeutics Inc | $24.6M | 0.5% | New |
| KARDKardigan Inc | $21.5M | 0.4% | New |
Best picks still held
How each current holding has done since the quarter it first appeared in its filings (up to six years back).
| Stock | Held since | Return since | Now worth |
|---|---|---|---|
| RVMDRevolution Medicines Inc | March 31, 2024 | +481.1% | $1.2B |
| OLMAOlema Pharmaceuticals Inc | March 31, 2023 | +260.5% | $108.5M |
| ORKAOruka Therapeutics Inc | December 31, 2025 | +214.0% | $204.1M |
| TARSTarsus Pharmaceuticals Inc | December 31, 2023 | +210.8% | $174.7M |
| SYRESpyre Therapeutics Inc | September 30, 2024 | +201.9% | $341.0M |
| Nuvalent IncCUSIP 670703107 | June 30, 2023 | +192.9% | $731.7M |
| EWTXEdgewise Therapeutics Inc | March 31, 2024 | +122.8% | $415.1M |
| Apogee Therapeutics IncCUSIP 03770N101 | March 31, 2024 | +99.7% | $209.2M |
| TNGXTango Therapeutics Inc | March 31, 2026 | +49.4% | $198.7M |
| VORVor Biopharma Inc | December 31, 2025 | +40.7% | $32.2M |
Sold off last quarter
- Arcellx IncCUSIP 03940C100 was $663.0M
- Centessa Pharmaceuticals PLCCUSIP 152309100 was $142.0M
- Terns Pharmaceuticals IncCUSIP 880881107 was $116.9M
- CYTKCytokinetics Inc was $97.6M
- ABVXAbivax Sa was $86.0M
- MAZEMaze Therapeutics Inc was $81.9M
- SRRKScholar Rock Hldg Corp was $60.3M
- MIRMMirum Pharmaceuticals Inc was $57.7M
- MANEVeradermics Inc was $33.2M
- Urogen Pharma LtdCUSIP M96088105 was $30.6M
Quarter by quarter
| Quarter | Its picks | S&P 500 |
|---|---|---|
| June 30, 2026 | +15.9% | +14.8% |
| March 31, 2026 | +9.2% | −4.6% |
| December 31, 2025 | +24.5% | +2.4% |
| September 30, 2025 | +33.6% | +7.8% |
| June 30, 2025 | −0.3% | +10.5% |
| March 31, 2025 | −18.4% | −4.6% |
| December 31, 2024 | −9.4% | +2.1% |
| September 30, 2024 | +17.7% | +5.4% |
| June 30, 2024 | −10.1% | +4.0% |
| March 31, 2024 | +7.0% | +10.0% |
| December 31, 2023 | +26.5% | +11.2% |
| September 30, 2023 | −6.1% | −3.6% |
| June 30, 2023 | +3.5% | +8.3% |
| March 31, 2023 | −8.9% | +7.0% |
| December 31, 2022 | +10.7% | +7.1% |
| September 30, 2022 | +14.2% | −5.3% |
| June 30, 2022 | −6.7% | −16.5% |
| March 31, 2022 | −14.8% | −4.9% |
Sources
Every number on this page points here. Each one links to the public record.
- 1SEC EDGAR: Paradigm Biocapital Advisors LP Form 13F filingshttps://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1855655&type=13F-HR&dateb=&owner=include&count=40CIK 1855655
- 2SEC: 13F for the quarter ended June 30, 2026https://www.sec.gov/Archives/edgar/data/1855655/000185565526000014/Filed August 14, 2026 · accession 0001855655-26-000014